A. Gómez

First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study

Enrique Aranda, Pilar García‐Alfonso, Manuel Benavides et al. · European Journal of Cancer · 2018 · 82 citations

Medicine, Oncology, Pharmacotherapy +16

Randomized study of weekly irinotecan plus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) as first-line chemotherapy for patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors Study

Enrique Aranda, M. Valladares, M. Martínez-Villacampa et al. · Annals of Oncology · 2008 · 27 citations

Medicine, Oncology, Pharmacology +12

Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and <3 baseline circulating tumour cells: the randomised phase II VISNÚ-2 study

Javier Sastre, Pilar García‐Alfonso, José María Viéitez et al. · ESMO Open · 2021 · 25 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

CYP2D6*4 polymorphism as blood predictive biomarker of breast cancer relapse in patients receiving adjuvant tamoxifen

Santiago González-Santiago, Ruth Zárate, Juan de la Haba-Rodríguez et al. · Journal of Clinical Oncology · 2007 · 20 citations

Medicine, Oncology, Pharmacology +17

Phase Ii Study of First-Line Mfolfox Plus Cetuximab (C) for 8 Cycles Followed By Mfolfox Plus C or Single Agent (S/A) C As Maintenance Therapy in Patients (P) with Metastatic Colorectal Cancer (Mcrc): the Macro-2 Trial (Spanish Cooperative Group for the Treatment of Digestive Tumors [Ttd])

Pilar Alfonso, Manuel Benavides, A. Ruiz et al. · Annals of Oncology · 2014 · 18 citations · Full text

Medicine, Oncology, Pharmacotherapy +14